HTML Microdata document

This HTML5 document contains 84 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n20	http://www.rxlist.com/cgi/generic3/
n2	http://linked.opendata.cz/resource/drugbank/drug/
n9	http://linked.opendata.cz/resource/drugbank/drug/DB00710/identifier/pdb/
dcterms	http://purl.org/dc/terms/
n8	http://linked.opendata.cz/resource/drugbank/drug/DB00710/identifier/bindingdb/
n12	http://linked.opendata.cz/resource/drugbank/drug/DB00710/identifier/pubchem-compound/
n18	http://linked.opendata.cz/resource/AHFS/
n23	http://linked.opendata.cz/resource/drugbank/company/
n28	http://linked.opendata.cz/resource/mesh/concept/
foaf	http://xmlns.com/foaf/0.1/
n16	http://linked.opendata.cz/resource/drugbank/dosage/
n13	http://linked.opendata.cz/resource/drugbank/drug/DB00710/identifier/pubchem-substance/
n7	http://linked.opendata.cz/resource/drugbank/drug/DB00710/identifier/drugbank/
n22	http://bio2rdf.org/drugbank:
n11	http://linked.opendata.cz/resource/drugbank/drug/DB00710/identifier/national-drug-code-directory/
adms	http://www.w3.org/ns/adms#
n25	http://linked.opendata.cz/resource/drugbank/patent/
n15	http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n6	http://linked.opendata.cz/resource/drugbank/drug/DB00710/identifier/chemspider/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n24	http://linked.opendata.cz/resource/drugbank/medicinal-product/
owl	http://www.w3.org/2002/07/owl#
n27	http://linked.opendata.cz/ontology/mesh/
n3	http://linked.opendata.cz/ontology/drugbank/
n30	http://www.drugs.com/cdi/
n4	http://linked.opendata.cz/resource/drugbank/property/
xsdh	http://www.w3.org/2001/XMLSchema#
n26	http://linked.opendata.cz/resource/drugbank/drug/DB00710/identifier/wikipedia/
n10	http://linked.opendata.cz/resource/drugbank/drug/DB00710/identifier/pharmgkb/
n21	http://linked.opendata.cz/resource/atc/
n17	http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item: n2:DB00710
rdf:type: n3:Drug
n3:description: Ibandronate is a nitrogen-containing bisphosphonate in the same class as alendronate and risedronate. Ibandronate inhibits osteoclast-mediated bone resorption. All of the bisphosphonates prevent the breakdown of bone by bone cells called osteoclasts. In persons who are at high risk for osteoporosis, bisphosphonates not only result in increased amounts of bone and bone strength, they also reduce the risk of hip fractures and other bone fractures.
n3:dosage: n16:271B4AEC-363D-11E5-9242-09173F13E4C5 n16:271B4AED-363D-11E5-9242-09173F13E4C5 n16:271B4AEE-363D-11E5-9242-09173F13E4C5
n3:generalReferences: # Epstein S, Zaidi M: Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis. Bone. 2005 Oct;37(4):433-40. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16046205
n3:group: approved investigational
n3:halfLife: 10-60 hours
n3:indication: For the treatment and prevention of osteoporosis in postmenopausal women.
n3:manufacturer: n23:271B4AE6-363D-11E5-9242-09173F13E4C5
owl:sameAs: n15:DB00710 n22:DB00710
dcterms:title: Ibandronate
adms:identifier: n6:54839 n7:DB00710 n8:12577 n9:BFQ n10:PA10270 n11:0004-0185-23 n12:60852 n13:46508134 n26:Ibandronate
n3:mechanismOfAction: The action of ibandronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting farnesyl pyrophosphate (FPP) synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.
n3:packager: n23:271B4AE4-363D-11E5-9242-09173F13E4C5 n23:271B4AE5-363D-11E5-9242-09173F13E4C5 n23:271B4AE2-363D-11E5-9242-09173F13E4C5 n23:271B4AE3-363D-11E5-9242-09173F13E4C5 n23:271B4AE1-363D-11E5-9242-09173F13E4C5
n3:patent: n25:7192938 n25:2346662 n25:4927814
n3:routeOfElimination: Ibandronate is eliminated by renal excretion. Unabsorbed ibandronate is eliminated unchanged in the feces.
n3:synonym: Ibandronic Acid Bondronat
n3:toxicity: LD<sub>50</sub> = 811 mg/kg (rat, oral), side effects include bronchitis, pneumonia and urinary tract infections.
n3:volumeOfDistribution: * 90 L
n17:hasAHFSCode: n18:92-00
n3:foodInteraction: Take on an empty stomach. All foods markedly reduce (up to 90%) ibandronate bioavailabilty. Take with plain water (not mineralized) at least 1 hour before any food. Bioavailability and effect on bone density are both impaired if the patient eats or drinks in less than 1 hour after taking this product. Drink a large glass of water and stay in an upright position for at least 60 minutes after taking this product.
n3:proteinBinding: 90.9 to 99.5% over an ibandronate concentration range of 2 to 10 ng/mL
n3:salt
n3:synthesisReference: Revital Lifshitz-Liron, Thomas Bayer, Judith Aronhime, Michael Pinchasov, "Solid and crystalline ibandronate sodium and processes for preparation thereof." U.S. Patent US20070179119, issued August 02, 2007.
n27:hasConcept: n28:M0197523
foaf:page: n20:boniva.htm n30:ibandronate.html
n3:IUPAC-Name: n4:271B4AF3-363D-11E5-9242-09173F13E4C5
n3:InChI: n4:271B4AF9-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula: n4:271B4AF8-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight: n4:271B4AF5-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight: n4:271B4AF6-363D-11E5-9242-09173F13E4C5
n3:SMILES: n4:271B4AF7-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility: n4:271B4AF1-363D-11E5-9242-09173F13E4C5 n4:271B4B09-363D-11E5-9242-09173F13E4C5
n3:logP: n4:271B4AF2-363D-11E5-9242-09173F13E4C5 n4:271B4AEF-363D-11E5-9242-09173F13E4C5 n4:271B4B0A-363D-11E5-9242-09173F13E4C5
n3:logS: n4:271B4AF0-363D-11E5-9242-09173F13E4C5
n17:hasATCCode: n21:M05BA06
n3:H-Bond-Acceptor-Count: n4:271B4AFF-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count: n4:271B4B00-363D-11E5-9242-09173F13E4C5
n3:InChIKey: n4:271B4AFA-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-: n4:271B4AFB-363D-11E5-9242-09173F13E4C5
n3:Polarizability: n4:271B4AFD-363D-11E5-9242-09173F13E4C5
n3:Refractivity: n4:271B4AFC-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count: n4:271B4AFE-363D-11E5-9242-09173F13E4C5
n3:absorption: Poorly absorbed (mean bioavailability following a 2.5 mg oral dose is about 0.6% compared to intravenous dosing). Absorption is impaired by any kind of food or drink other than plain water.
n3:affectedOrganism: Humans and other mammals
n3:casRegistryNumber: 114084-78-5
n3:category
n3:clearance: * 84 to 160 mL/min [IV administration]
n3:containedIn: n24:271B4AEB-363D-11E5-9242-09173F13E4C5 n24:271B4AEA-363D-11E5-9242-09173F13E4C5 n24:271B4AE8-363D-11E5-9242-09173F13E4C5 n24:271B4AE9-363D-11E5-9242-09173F13E4C5 n24:271B4AE7-363D-11E5-9242-09173F13E4C5
n3:Bioavailability: n4:271B4B05-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter: n4:271B4B07-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule: n4:271B4B08-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings: n4:271B4B04-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge: n4:271B4B03-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five: n4:271B4B06-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name: n4:271B4AF4-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-: n4:271B4B01-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-: n4:271B4B02-363D-11E5-9242-09173F13E4C5